Difficulty: Medium
Average Score: 72%
Practice
A 3-month-old male infant is brought to the emergency department by his parents following a 30-min seizure at home. In the emergency department, the child is not seizing and is afebrile. Prenatal history is insignificant except for a few apparently mild illnesses experienced by his mother. They own three cats. A CT scan of the infant├óÔé¼Ôäós head reveals intracerebral calcifications and mild ventricular hypertrophy. The infant is given pyrimethamine for toxoplasmosis. Which of the following describes pyrimethamine├óÔé¼Ôäós mechanism of action?
Correct answer
A
Rationale
The correct answer is A) Inhibition of dihydrofolate reductase. Pyrimethamine is a medication used in the treatment of toxoplasmosis, a parasitic infection caused by Toxoplasma gondii. Pyrimethamine works by inhibiting the enzyme dihydrofolate reductase, which is essential for the parasite to synthesize purines and pyrimidines necessary for DNA replication. By blocking this enzyme, pyrimethamine disrupts the folate pathway in the parasite, leading to impaired nucleic acid synthesis and ultimately, the death of the parasite.
Option B) Inhibition of dihydropteroate synthetase is incorrect because this mechanism of action is associated with sulfonamides, not pyrimethamine.
Option C) Inhibition of nucleic acid synthesis is a broad statement and does not specifically address the mechanism of action of pyrimethamine via dihydrofolate reductase inhibition.
Option D) Membrane depolarization is not a mechanism of action associated with pyrimethamine in the context of treating toxoplasmosis.
Understanding the mechanism of action of medications is crucial for healthcare providers to effectively treat patients and manage drug therapy. In this case, knowing that pyrimethamine targets dihydrofolate reductase provides insight into how it disrupts the parasite's metabolism and aids in selecting appropriate treatment for toxoplasmosis. This knowledge is essential for pharmacology education and clinical practice.
Option B) Inhibition of dihydropteroate synthetase is incorrect because this mechanism of action is associated with sulfonamides, not pyrimethamine.
Option C) Inhibition of nucleic acid synthesis is a broad statement and does not specifically address the mechanism of action of pyrimethamine via dihydrofolate reductase inhibition.
Option D) Membrane depolarization is not a mechanism of action associated with pyrimethamine in the context of treating toxoplasmosis.
Understanding the mechanism of action of medications is crucial for healthcare providers to effectively treat patients and manage drug therapy. In this case, knowing that pyrimethamine targets dihydrofolate reductase provides insight into how it disrupts the parasite's metabolism and aids in selecting appropriate treatment for toxoplasmosis. This knowledge is essential for pharmacology education and clinical practice.